Galen
Executive Summary
Branded generic Estrace (estradiol) tablets acquired by Galen from Bristol for $95 mil.; estrogen replacement therapy generated sales of $40.5 mil. in 2000. Bristol sold the U.S. rights to its Apothecon subsidiary's line of finished generic drugs to Novartis last year, but retained the branded generics (1"The Pink Sheet" Dec. 18, 2000, p. 5)
You may also be interested in...
Lilly Sells Sarafem: Galen Adds Drug To Women’s Health Line For $295 Mil.
Galen is adding Sarafem to its line of women's health products through a $295 mil. deal with Lilly
Lilly Sells Sarafem: Galen Adds Drug To Women’s Health Line For $295 Mil.
Galen is adding Sarafem to its line of women's health products through a $295 mil. deal with Lilly
Apothecon To Continue As Bristol Unit After Sale Of Generics To Novartis
Bristol Myers-Squibb will continue to market generic drugs internationally and its branded generics in the U.S. following the sale of U.S. rights to its Apothecon subsidiary's line of finished generic drugs to Novartis.